Skip to main content
Year archive

Sanofi — 2020 filings

All 234 regulatory filings released by Sanofi (SAN) in 2020, sourced directly from the official regulator.

234 Filings
2020 Period
2020 filings (234)
Filing Released Lang
Sanofi : Informations relatives au nombre total de droits de vote et d’actions - Novembre 2020
Share Issue/Capital Change
2020-12-28 French
Sanofi: Information concerning the total number of voting rights and shares - November 2020
Declaration of Voting Results & Voting Rights Announcements
2020-12-28 English
6-K
Foreign Filer Report
2020-12-18 English
Mise en ligne du document « Q4 2020 Memorandum for modelling purposes »
Report Publication Announcement
2020-12-17 French
Availability of the Q4 2020 Memorandum for modelling purposes
Report Publication Announcement
2020-12-17 English
Sanofi renouvelle son partenariat avec l'OMS pour lutter contre les maladies tropicales négligées et éliminer la maladie du sommeil avant 2030
Regulatory Filings
2020-12-15 French
Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030
Regulatory Filings
2020-12-15 English
6-K
Foreign Filer Report
2020-12-11 English
Le CHMP recommande l’approbation de Plavix® (clopidogrel) en association avec de l’aspirine après certaines formes d’accident vasculaire cérébral de l’adulte
Regulatory Filings
2020-12-11 French
CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes
Regulatory Filings
2020-12-11 English
Sanofi et GSK annoncent un retard dans leur programme de vaccin adjuvanté à protéine recombinante contre la Covid-19 afin d’améliorer la réponse immunitaire chez les personnes âgées
Regulatory Filings
2020-12-11 French
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
Environmental & Social Information
2020-12-11 English
Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities
Capital/Financing Update
2020-12-09 English
Sanofi se place à l’avant-garde de la finance durable dans le secteur pharmaceutique avec la signature de ses deux premières lignes de crédit renouvelables indexées sur des indicateurs de développemen
Capital/Financing Update
2020-12-09 French
6-K
Foreign Filer Report
2020-12-03 English
Sanofi : Informations relatives au nombre total de droits de vote et d’actions - Octobre 2020
Regulatory Filings
2020-11-30 French
Sanofi: Information concerning the total number of voting rights and shares - October 2020
Regulatory Filings
2020-11-30 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2020-11-30 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2020-11-30 English
La Commission européenne approuve Dupixent® (dupilumab), le premier et le seul médicament biologique indiqué pour le traitement de la dermatite atopique sévère de l’enfant âgé de 6 à 11 ans
Regulatory Filings
2020-11-30 French
Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
Earnings Release FY 2020
2020-11-30 English
6-K
Foreign Filer Report
2020-11-25 English
Sanofi: Disclosure of trading in own shares
Regulatory Filings
2020-11-23 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2020-11-23 English
La Commission européenne approuve MenQuadfi®, la toute dernière innovation en matière de vaccin méningococcique (MenACWY), indiqué à partir de l’âge de 12 mois
Regulatory Filings
2020-11-23 French
European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
Regulatory Filings
2020-11-23 English
6-K
Foreign Filer Report
2020-11-19 English
European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
Regulatory Filings
2020-11-18 English
La Commission européenne approuve Supemtek® (vaccin antigrippe recombinant quadrivalent) pour la prévention de la grippe chez l’adulte à partir de 18 ans
Regulatory Filings
2020-11-18 French
Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia
Regulatory Filings
2020-11-18 English
La FDA accorde une procédure accélérée au rilzabrutinib pour le traitement de la thrombocytopénie immune
Regulatory Filings
2020-11-18 French
FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
Legal Proceedings Report
2020-11-18 English
La FDA publie une lettre de réponse complète au sujet du sutimlimab, un médicament expérimental pour le traitement de l’hémolyse chez l’adulte atteint de la maladie des agglutinines froides
Regulatory Filings
2020-11-14 French
FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
Legal Proceedings Report
2020-11-14 English
6-K
Foreign Filer Report
2020-11-04 English
Sanofi propose d’acquérir Kiadis, une entreprise spécialisée dans les produits d’immunothérapie à base de cellules au stade clinique
M&A Activity
2020-11-02 French
Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products
M&A Activity
2020-11-02 English
6-K
Foreign Filer Report
2020-10-30 English
6-K
Foreign Filer Report
2020-10-29 English
L’Office européen des brevets statue en faveur de Sanofi et Regeneron au sujet de Praluent® (alirocumab)
Legal Proceedings Report
2020-10-29 French
European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)
Legal Proceedings Report
2020-10-29 English
Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER
Earnings Release Q3 2020
2020-10-29 English
Croissance du BNPA(1) des activités de 8,8% à TCC au troisième trimestre 2020
Earnings Release Q3 2020
2020-10-29 French
Sanofi va évaluer la sécurité et l’efficacité d’un nouveau candidat expérimental, THOR-707, en association avec KEYTRUDA® (pembrolizumab), dans le but d’établir une nouvelle option thérapeutique en on
Regulatory Filings
2020-10-29 French
Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology
Regulatory Filings
2020-10-29 English
Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
Regulatory Filings
2020-10-28 English
Sanofi et GSK vont apporter leur soutien au mécanisme COVAX avec 200 millions de doses de leur vaccin adjuvanté à base de protéine recombinante contre la COVID-19
Regulatory Filings
2020-10-28 French
6-K
Foreign Filer Report
2020-10-27 English
Sanofi : Informations relatives au nombre total de droits de vote et d'actions - Septembre 2020
Regulatory Filings
2020-10-27 French
Sanofi: Information concerning the total number of voting rights and shares - September 2020
Major Shareholding Notification
2020-10-27 English
Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
Earnings Release FY 2020
2020-10-26 English
Dupixent® (dupilumab): de nouvelles données pivotales montrant une amélioration significative des symptômes de l’œsophagite à éosinophiles ont été présentées pour la première fois lors de congrès scie
Regulatory Filings
2020-10-26 French
6-K
Foreign Filer Report
2020-10-16 English
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
Regulatory Filings
2020-10-16 English
Le CHMP recommande l’approbation de Dupixent® (dupilumab) pour le traitement de la dermatite atopique sévère de l’enfant âgé de 6 à 11 ans
Regulatory Filings
2020-10-16 French
Le candidat-vaccin à ARNm contre la COVID-19 de Sanofi et Translate Bio a induit la production de concentrations élevées d’anticorps dans le cadre d’études précliniques
Earnings Release Q4 2020
2020-10-15 French
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
Earnings Release Q4 2020
2020-10-15 English
Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
Earnings Release Q1 2021
2020-10-13 English
6-K
Foreign Filer Report
2020-10-06 English
L’EMA accepte la soumission réglementaire de l’avalglucosidase alpha, un nouveau traitement de référence potentiel de la maladie de Pompe
Regulatory Filings
2020-10-02 French
EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
Regulatory Filings
2020-10-02 English
6-K
Foreign Filer Report
2020-10-01 English
Sanofi: Information concerning the total number of voting rights and shares - August 2020
Declaration of Voting Results & Voting Rights Announcements
2020-10-01 English
Sanofi: Informations relatives au nombre total de droits de vote et d’actions - Août 2020
Declaration of Voting Results & Voting Rights Announcements
2020-10-01 French
Sanofi finalise l’acquisition de Principia Biopharma Inc
M&A Activity
2020-09-28 French
Sanofi completes Principia Biopharma Inc. acquisition
M&A Activity
2020-09-28 English
FORM 6-K
Foreign Filer Report
2020-09-28 English
SC TO-T/A Filing
Regulatory Filings
2020-09-28 English
Mise en ligne du document «Q3 2020 Memorandum for modelling purposes»
Report Publication Announcement
2020-09-25 French
Availability of the Q3 2020 Memorandum for modelling purposes
Report Publication Announcement
2020-09-25 English
6-K
Foreign Filer Report
2020-09-22 English
Sanofi et GSK signent des accords avec le Gouvernement du Canada pour la fourniture de jusqu’à 72 millions de doses de leur vaccin adjuvanté contre la COVID-19
Regulatory Filings
2020-09-22 French
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
Regulatory Filings
2020-09-22 English
Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.
M&A Activity
2020-09-22 English
Sanofi : Expiration de la période d’attente prévue par la loi Hart-Scott-Rodino pour l’acquisition de Principia Biopharma Inc.
M&A Activity
2020-09-22 French
SC TO-T/A Filing
Regulatory Filings
2020-09-22 English
Une présentation de dernière minute au congrès de l’ESMO montre qu’une monothérapie par Libtayo® (cemiplimab) augmente la survie globale des patients atteints d’un cancer du poumon non à petites cellu
Earnings Release FY 2020
2020-09-21 French
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of =50%
Earnings Release FY 2020
2020-09-21 English
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of =50%
Earnings Release FY 2020
2020-09-21 English
Une présentation de dernière minute au congrès de l’ESMO montre qu’une monothérapie par Libtayo® (cemiplimab) augmente la survie globale des patients atteints d’un cancer du poumon non à petites cellu
Regulatory Filings
2020-09-21 French
Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO
Regulatory Filings
2020-09-18 English
Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation
Board/Management Information
2020-09-18 English
Le Dr Jean-Christophe Rufin est nommé Président de la Fondation d’entreprise Sanofi Espoir
Board/Management Information
2020-09-18 French
6-K
Foreign Filer Report
2020-09-14 English
La FDA accorde la désignation de Breakthrough Therapy à Dupixent® (dupilumab) dans le traitement de l’œsophagite à éosinophiles
Regulatory Filings
2020-09-14 French
FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
Regulatory Filings
2020-09-14 English
SC TO-T/A Filing
Regulatory Filings
2020-09-14 English
Sanofi : Information concerning the total number of voting rights and shares - July 2020
Regulatory Filings
2020-09-11 English
Sanofi : Informations relatives au nombre total de droits de vote et d’actions - Juillet 2020
Share Issue/Capital Change
2020-09-11 French
Le New England Journal of Medicine publie les résultats finaux positifs d’une étude de phase I/IIa consacrée au BIVV001 dans le traitement de l’hémophilie A sévèr
Earnings Release FY 2020
2020-09-10 French
New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A
Regulatory Filings
2020-09-10 English
6-K
Foreign Filer Report
2020-09-08 English
Les données à long terme relatives à Dupixent® (dupilumab) montrent une amélioration soutenue de la fonction respiratoire et une réduction des exacerbations sévères chez les adultes et adolescents sou
Investor Presentation
2020-09-08 French
Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma
Earnings Release FY 2020
2020-09-08 English
Sanofi et GSK lancent un essai clinique de phase I/II de leur candidat-vaccin adjuvanté à base de protéine recombinante contre la COVID-19
Regulatory Filings
2020-09-03 French
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
Regulatory Filings
2020-09-03 English
Sanofi fait le point sur l’essai de phase III de Kevzara® (sarilumab) mené hors États-Unis chez des patients présentant une forme sévère ou critique de COVID-19
Earnings Release FY 2020
2020-09-01 French
Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.
Legal Proceedings Report
2020-09-01 English
Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.
M&A Activity
2020-08-28 English
SC TO-T Filing
Regulatory Filings
2020-08-28 English
SC TO-C Filing
Regulatory Filings
2020-08-18 English
6-K
Foreign Filer Report
2020-08-17 English
Sanofi va acquérir Principia Biopharma
M&A Activity
2020-08-17 French
Sanofi to acquire Principia Biopharma
M&A Activity
2020-08-17 English
6-K
Foreign Filer Report
2020-08-07 English
6-K
Foreign Filer Report
2020-08-05 English
Regulatory Filings 2020
Regulatory Filings
2020-08-04 English
Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine
Regulatory Filings
2020-07-31 English
Sanofi et GSK en discussion avancée avec l'Union européenne pour fournir jusqu'à 300 millions de doses de vaccin COVID-19
Regulatory Filings
2020-07-31 French
Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine
Regulatory Filings
2020-07-31 English
Sanofi et GSK sélectionnés par le programme Operation Warp Speed pour fournir 100 millions de doses du vaccin contre la COVID-19 au gouvernement des États-Unis
Regulatory Filings
2020-07-31 French
Le nirsevimab a permis de réduire les infections par le virus respiratoire syncytial nécessitant des soins médicaux chez des nourrissons prématurés en bonne santé dans le cadre d’un essai de phase IIb
Earnings Release FY 2020
2020-07-30 French
Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial
Regulatory Filings
2020-07-30 English
Mise en ligne du rapport financier semestriel 2020 de Sanofi
Report Publication Announcement
2020-07-29 French
Online availability of Sanofi’s half-year financial report for 2020
Report Publication Announcement H2 2020
2020-07-29 English
6-K
Foreign Filer Report
2020-07-29 English
Sanofi: rapport financier semestriel 2020
Interim / Quarterly Report H2 2020
2020-07-29 French
6-K
Foreign Filer Report
2020-07-29 English
FORM 4 SUBMISSION
Director's Dealing
2020-07-29 English
Sanofi annonce une croissance du BNPA(1) des activités de 9,2%(2) au S1 2020 soutenue par la transformation
Earnings Release H1 2020
2020-07-29 French
Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
Earnings Release H2 2020
2020-07-29 English
Sanofi et GSK concluent un accord avec le gouvernement britannique pour fournir jusqu’à 60 millions de doses du vaccin contre la Covid-19
Regulatory Filings
2020-07-29 French
Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
Earnings Release FY 2020
2020-07-29 English
FORM 3 SUBMISSION
Director's Dealing
2020-07-24 English
Sanofi : Informations relatives au nombre total de droits de vote et d’actions - Juin 2020
Share Issue/Capital Change
2020-07-21 French
Sanofi: Information concerning the total number of voting rights and shares - June 2020
Declaration of Voting Results & Voting Rights Announcements
2020-07-21 English
6-K
Foreign Filer Report
2020-07-07 English
Mise en ligne du document « Pre-quarterly Results Communication »
Report Publication Announcement
2020-07-06 French
Availability of the Pre-quarterly Results Communication
Report Publication Announcement
2020-07-06 English
Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
Earnings Release Q3 2020
2020-07-02 English
Sanofi et Regeneron font le point sur l’essai de phase III consacré à Kevzara® (sarilumab) aux États-Unis chez des patients COVID-19
Earnings Release Q3 2020
2020-07-02 French
11-K
Regulatory Filings
2020-06-26 English
11-K
Regulatory Filings
2020-06-26 English
6-K
Foreign Filer Report
2020-06-24 English
Journée virtuelle dédiée à la R&D de Sanofi : présentation des capacités et plateformes technologiques ainsi que l’expertise dans les voies de signalisation des maladies, pour le développement de médi
Investor Presentation
2020-06-23 French
Sanofi’s virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients
Investor Presentation
2020-06-23 English
Sanofi et Translate Bio élargissent leur collaboration pour développer des vaccins à ARNm contre toutes les catégories de maladies infectieuses
Regulatory Filings
2020-06-23 French
Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas
Environmental & Social Information
2020-06-23 English
Sanofi: Information concerning the total number of voting rights and shares - May 2020
Declaration of Voting Results & Voting Rights Announcements
2020-06-19 English
Sanofi : Informations relatives au nombre total de droits de vote et d’actions - Mai 2020
Declaration of Voting Results & Voting Rights Announcements
2020-06-19 French
Sanofi présente les données intermédiaires positives de sécurité et d’efficacité à long terme de l’étude de prolongation de phase II du fitusiran chez des personnes atteintes d’hémophilie A ou B, avec
Earnings Release FY 2020
2020-06-19 French
Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors
Earnings Release FY 2020
2020-06-19 English
Dupixent® (dupilumab) approuvé en Chine pour le traitement de la dermatite atopique modérée à sévère de l’adulte
Regulatory Filings
2020-06-19 French
Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis
Regulatory Filings
2020-06-19 English
6-K
Foreign Filer Report
2020-06-17 English
L’enzymothérapie substitutive expérimentale de Sanofi a permis d’observer une amélioration cliniquement significative des manifestations sévères de la forme tardive de la maladie de Pompe
Earnings Release FY 2020
2020-06-16 French
Sanofi’s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease
Earnings Release H2 2020
2020-06-16 English
Sanofi investit pour faire de la France son pôle d’excellence mondial dans la recherche et la production de vaccins
Regulatory Filings
2020-06-16 French
Sanofi invests to make France its world class center of excellence in vaccine research and production
Regulatory Filings
2020-06-16 English
FORM 6-K
Foreign Filer Report
2020-06-12 English
6-K
Foreign Filer Report
2020-06-05 English
6-K
Foreign Filer Report
2020-06-03 English
6-K
Foreign Filer Report
2020-05-27 English
S-8
Registration Form
2020-05-26 English
6-K
Foreign Filer Report
2020-05-26 English
6-K
Foreign Filer Report
2020-05-22 English
Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R&D day event
Investor Presentation
2020-05-18 English
FORM 6-K
Foreign Filer Report
2020-05-14 English
S-8 POS
Regulatory Filings
2020-05-13 English
6-K
Foreign Filer Report
2020-05-07 English
6-K
Foreign Filer Report
2020-04-29 English
6-K
Foreign Filer Report
2020-04-27 English
SD
Regulatory Filings
2020-04-23 English
FORM 6-K
Foreign Filer Report
2020-04-20 English
6-K
Foreign Filer Report
2020-04-15 English
6-K
Foreign Filer Report
2020-04-07 English
6-K
Foreign Filer Report
2020-04-02 English
6-K
Foreign Filer Report
2020-03-30 English
15-12B/A
Regulatory Filings
2020-03-18 English
15-12B
Regulatory Filings
2020-03-16 English
6-K
Foreign Filer Report
2020-03-06 English
IRANNOTICE
Regulatory Filings
2020-03-05 English
20-F
Annual Report FY 2019
2020-03-05 English
Delisting Announcement 2020
Delisting Announcement
2020-03-04 English
Sanofi : Information sur les conditions de départ d'Olivier Brandicourt, Directeur Général
Remuneration Information
2020-03-04 French
Sanofi: Information on the Conditions for the Departure From Office of Olivier Brandicourt, Chief Executive Officer
Remuneration Information
2020-03-04 English
Sanofi's Board of Directors proposes the appointment of Rachel Duan and Lise Kingo as independent directors
Board/Management Information
2020-03-04 English
Le Conseil d’administration de Sanofi propose la nomination de Rachel Duan et de Lise Kingo aux postes d’administrateurs indépendants
Board/Management Information
2020-03-04 French
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2020-03-03 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2020-03-03 English
Sanofi : La FDA approuve Sarclisa® (isatuximab-irfc) pour le traitement du myélome multiple en rechute ou réfractaire
Regulatory Filings
2020-03-02 French
Sanofi : FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Regulatory Filings
2020-03-02 English
Sanofi : informations relatives au nombre total de droits de vote et d’actions, janvier 2020
Share Issue/Capital Change
2020-02-25 French
Sanofi: information concerning the total number of voting rights and shares, January 2020
Share Issue/Capital Change
2020-02-25 English
6-K
Foreign Filer Report
2020-02-25 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2020-02-24 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2020-02-24 English
Sanofi a l’ambition de créer un leader européen des principes actifs pharmaceutiques (API*)
Regulatory Filings
2020-02-24 French
Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*)
Capital/Financing Update
2020-02-24 English
Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine
Regulatory Filings
2020-02-18 English
Sanofi s’associe au ministère américain de la Santé et des Services sociaux pour développer un vaccin contre le nouveau coronavirus
Regulatory Filings
2020-02-18 French
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2020-02-17 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2020-02-17 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2020-02-10 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2020-02-10 English
SC 13G/A AMD NO 1
Major Shareholding Notification
2020-02-10 English
SC 13G/A
Major Shareholding Notification
2020-02-10 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-10 English
6-K
Foreign Filer Report
2020-02-06 English
Sanofi réalise un solide BNPA des activités 2019 en croissance de 6,8% à TCC
Earnings Release FY 2019
2020-02-06 French
Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
Earnings Release FY 2019
2020-02-06 English
Sanofi : Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis
Regulatory Filings
2020-02-06 English
Sanofi : L’essai de phase II de l’inhibiteur BTK à pénétration cérébrale de Sanofi atteint son critère d’évaluation principal dans le traitement de la sclérose en plaques rémittente-récurrente
Regulatory Filings
2020-02-06 French
Sanofi : Déclaration des transactions sur actions propres
Regulatory Filings
2020-02-03 French
Sanofi: Disclosure of trading in own shares
Regulatory Filings
2020-02-03 English
FORM 6-K
Foreign Filer Report
2020-02-03 English
Sanofi : Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency
Earnings Release FY 2020
2020-01-30 English
Sanofi : Premiers résultats positifs pour l’olipudase alfa, le premier et le seul médicament expérimental au stade de développement avancé pour le traitement du déficit en sphingomyélinase acide
Regulatory Filings
2020-01-30 French
Sanofi : La FDA accepte d’accorder un examen prioritaire à Dupixent® (dupilumab) dans le traitement de la dermatite atopique modérée à sévère de l’enfant âgé de 6 à 11 ans
Regulatory Filings
2020-01-28 French
Sanofi : FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
Regulatory Filings
2020-01-28 English
Regulatory Filings 2020
Regulatory Filings
2020-01-27 English
Sanofi: Disclosure of trading in own shares
Regulatory Filings
2020-01-27 English
Sanofi : Déclaration des transactions sur actions propres
Regulatory Filings
2020-01-27 French
FORM 6-K
Foreign Filer Report
2020-01-23 English
Sanofi : Sanofi finalise l’acquisition de Synthorx, Inc.
M&A Activity
2020-01-23 French
Sanofi : Sanofi Completes Acquisition of Synthorx, Inc.
M&A Activity
2020-01-23 English
SC TO-T/A Filing
Regulatory Filings
2020-01-23 English
SC TO-T/A Filing
Regulatory Filings
2020-01-21 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2020-01-20 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2020-01-20 English
Sanofi : Sanofi annonce l’expiration de la période d’attente prévue par la loi Hart-Scott-Rodino pour l’acquisition de Synthorx
M&A Activity
2020-01-20 French
Sanofi : Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Synthorx
M&A Activity
2020-01-20 English
Sanofi: information concerning the total number of voting rights and shares, December 2019
Declaration of Voting Results & Voting Rights Announcements
2020-01-17 English
Sanofi : informations relatives au nombre total de droits de vote et d’actions, décembre 2019
Declaration of Voting Results & Voting Rights Announcements
2020-01-17 French
Sanofi: Disclosure of trading in own shares
Regulatory Filings
2020-01-14 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2020-01-14 English
Regulatory Filings 2020
Regulatory Filings
2020-01-14 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2020-01-09 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2020-01-09 English
Sanofi : Mise en ligne du document «Pre-quarterly Results Communication »
Report Publication Announcement
2020-01-09 French
Sanofi : Availability of the Pre-quarterly Results Communication
Report Publication Announcement
2020-01-09 English
SC TO-T/A Filing
Regulatory Filings
2020-01-09 English
Regulatory Filings 2020
Regulatory Filings
2020-01-07 English
SC TO-T/A Filing
Regulatory Filings
2020-01-07 English